Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kheng Newick

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Molecular Therapy Oncolytics|May 11, 2016
Chimeric antigen receptor T-cell therapy for solid tumorsKheng Newick, Edmund Moon, Steven M Albelda
Annual Review of Medicine|November 19, 2016
CAR T Cell Therapy for Solid TumorsKheng Newick, Shaun O'Brien, Edmund Moon, et al.
DNA Repair|December 17, 2009
Non-specific DNA binding interferes with the efficient excision of oxidative lesions from chromatin by the human DNA glycosylase, NEIL1Ian D Odell, Kheng Newick, Nicholas H Heintz, et al.
Plos One|July 5, 2012
Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cellsKheng Newick, Brian Cunniff, Kelsey Preston, et al.
Cancer Immunology Research|April 6, 2016
Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A LocalizationKheng Newick, Shaun O'Brien, Jing Sun, et al.
Journal of Cellular Physiology|September 29, 2012
Mitochondrial-targeted nitroxides disrupt mitochondrial architecture and inhibit expression of peroxiredoxin 3 and FOXM1 in malignant mesothelioma cellsBrian Cunniff, Kira Benson, Jason Stumpff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive TransferEdmund K Moon, Raghuveer Ranganathan, Evgeniy Eruslanov, et al.
Cancer Research|March 17, 2016
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid TumorsXiaojun Liu, Raghuveer Ranganathan, Shuguang Jiang, et al.
International Journal of Cancer|December 26, 2015
HDAC5 controls the functions of Foxp3(+) T-regulatory and CD8(+) T cellsHaiyan Xiao, Jing Jiao, Liqing Wang, et al.
Cancer Immunology Research|May 6, 2015
Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric ImmunoreceptorsEnxiu Wang, Liang-Chuan Wang, Ching-Yi Tsai, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Molecular Therapy Oncolytics|May 11, 2016
Chimeric antigen receptor T-cell therapy for solid tumorsKheng Newick, Edmund Moon, Steven M Albelda
Annual Review of Medicine|November 19, 2016
CAR T Cell Therapy for Solid TumorsKheng Newick, Shaun O'Brien, Edmund Moon, et al.
DNA Repair|December 17, 2009
Non-specific DNA binding interferes with the efficient excision of oxidative lesions from chromatin by the human DNA glycosylase, NEIL1Ian D Odell, Kheng Newick, Nicholas H Heintz, et al.
Plos One|July 5, 2012
Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cellsKheng Newick, Brian Cunniff, Kelsey Preston, et al.
Cancer Immunology Research|April 6, 2016
Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A LocalizationKheng Newick, Shaun O'Brien, Jing Sun, et al.
Journal of Cellular Physiology|September 29, 2012
Mitochondrial-targeted nitroxides disrupt mitochondrial architecture and inhibit expression of peroxiredoxin 3 and FOXM1 in malignant mesothelioma cellsBrian Cunniff, Kira Benson, Jason Stumpff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive TransferEdmund K Moon, Raghuveer Ranganathan, Evgeniy Eruslanov, et al.
Cancer Research|March 17, 2016
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid TumorsXiaojun Liu, Raghuveer Ranganathan, Shuguang Jiang, et al.
International Journal of Cancer|December 26, 2015
HDAC5 controls the functions of Foxp3(+) T-regulatory and CD8(+) T cellsHaiyan Xiao, Jing Jiao, Liqing Wang, et al.
Cancer Immunology Research|May 6, 2015
Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric ImmunoreceptorsEnxiu Wang, Liang-Chuan Wang, Ching-Yi Tsai, et al.
Pageof 2